<?xml version='1.0'?>
<!DOCTYPE art SYSTEM 'http://www.biomedcentral.com/xml/article.dtd'>
<art>
   <ui>ar160</ui>
   <ji>ARJ</ji>
   <fm>
      <dochead>Meeting abstract</dochead>
      <bibl>
         <title>
            <p>Anti-inflammatory activity of statins: potential use in the anti-phospholipid syndrome</p>
         </title>
         <aug>
            <au id="A1">
               <snm>Meroni</snm>
               <fnm>PL</fnm>
               <insr iid="I1"/>
            </au>
         </aug>
         <insg>
            <ins id="I1">
               <p>Department of Internal Medicine, IRCCS Istituto Auxologico Italiano, University of Milan, Italy</p>
            </ins>
         </insg>
         <source>Arthritis Res</source>
         <supplement>
            <title>
               <p>21st European Workshop for Rheumatology Research</p>
            </title>
            <note>Meeting abstracts</note>
         </supplement>
         <conference>
            <title>
               <p>21st European Workshop for Rheumatology Research</p>
            </title>
            <location>Vienna, Austria</location>
            <date-range>1&#8211;4 March 2001</date-range>
         </conference>
         <issn>1465-9905</issn>
         <pubdate>2001</pubdate>
         <volume>3</volume>
         <issue>Suppl A</issue>
         <fpage>L013</fpage>
         <xrefbib>
            <pubid idtype="doi">10.1186/ar160</pubid>
         </xrefbib>
      </bibl>
      <history>
         <rec>
            <date>
               <day>15</day>
               <month>1</month>
               <year>2001</year>
            </date>
         </rec>
         <pub>
            <date>
               <day>26</day>
               <month>1</month>
               <year>2001</year>
            </date>
         </pub>
      </history>
      <cpyrt>
         <year>2001</year>
         <collab>2001 BioMed Central Ltd</collab>
      </cpyrt>
   </fm>
   <meta>
      <classifications>
         <classification type="BMC" subtype="old_arx_id">ar-3-2-l013</classification>
      </classifications>
   </meta>
   <bdy>
      <sec>
         <st>
            <p>Background</p>
         </st>
         <p>Hydroxymethylglutaryl Coenzyme A reductase (HMGCoA-red) inhibitors are cholesterol lowering drugs which display pleiotropic effects on several cell types including endothelial cells (EC). Patients with antiphospholipid syndrome (APS) are characterized by the persistent presence of antiphospholipid antibodies (aPL) and by a high incidence of recurrent thrombotic events. aPL have been demonstrated to bind and activate cultured human EC thus contributing to a prothrombotic state. We evaluated the ability of HMGCoA inhibitors to affect the EC activation induced <it>in vitro</it> by aPL and in particular by antibodies reacting with the PL-binding protein &#946;2 glycoprotein I (&#946;2GPI). Both human monoclonal IgM and polyclonal IgG anti-&#946;2GPI antibodies were used. EC activation was evaluated as adhesion molecule (ADM) expression and cytokine production.</p>
      </sec>
      <sec>
         <st>
            <p>Methods</p>
         </st>
         <p>ADM expression was evaluated by a cell ELISA. EC were incubated with human recombinant (hr) IL-1&#946; (50 U/ml), hr TNF&#945; (10 ng/ml), LPS (20 ng/ml) or with human anti-&#946;2GPI antibodies (100 &#956;g/ml) for 4 hr for E-Selectin expression and for 20 hr for ICAM-1 evaluation. Cytokine production was investigated by using the RiboQuant<sup>&#8482;</sup><it>in vitro</it> transcription assay to measure IL-6 mRNA expression. As control, EC monolayers were incubated with irrelevant monoclonal or polyclonal antibodies or medium alone. The same experiments were carried out with EC monolayers pre-incubated overnight with fluvastatin or simvastatin (1-10 &#956;M) in the absence or presence of mevalonate (100 &#956;M). E-Selectin specific NF&#954;B expression was also evaluated by the gel-shift assay.</p>
      </sec>
      <sec>
         <st>
            <p>Results</p>
         </st>
         <p>Both statins inhibited in a concentration dependent-manner the ADM expression induced by anti-&#946;2GPI antibodies as well as those induced by the other agonists, being fluvastatin more efficient than simvastatin. Fluvastatin also down-regulated the mRNA expression specific for IL-6 and significantly inhibited E-Selectin NF&#954;B DNA-binding. The simultaneous addition of meval-onate to fluvastatin completely prevented the drug inhibitory effect.</p>
      </sec>
      <sec>
         <st>
            <p>Conclusions</p>
         </st>
         <p>These data demonstrates for the first time that statins (and particularly fluvastatin) are able to inhibit an endothelial pro-adhesive and pro-inflammatory phenotype induced by different stimuli including anti-&#946;2GPI antibodies or pro-inflammatory cytokines. Altogether these findings suggest a potential usefulness for statins in the prevention of the APS pro-atherothrombotic state.</p>
      </sec>
   </bdy>
</art>
